This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donehower, R. C. Search for Related Content PubMed PubMed Citation Articles by Donehower, R. C.

The Clinical Development of Paclitaxel: A Successful Collaboration of Academia, Industry and the National Cancer Institute

Division of Medical Oncology, Johns Hopkins Oncology Center, Baltimore, Maryland, USA

Correspondence: Ross C. Donehower, M.D., Division of Medical Oncology, Johns Hopkins Oncology Center, 600 North Wolfe Street, Baltimore, MD 21287-8936, USA. Telephone: 410-955-8838; Fax: 410-955-0125.

The successful development of paclitaxel as an important new antineoplastic agent with the potential to have an impact on a number of human cancers was possible as a result of significant contributions from individuals and groups with diverse areas of interest and expertise.

The advancement of paclitaxel through the preclinical and clinical evaluation which ultimately led to its approval, as well as surmounting the regulatory hurdles which were faced required the close collaboration of individual investigators at academic institutions, the pharmaceutical industry (Bristol-Myers Squibb) and the National Cancer Institute. The latter stages of this developmental effort can be viewed as a prime example of the potential of the Cooperative Research and Development Agreement mechanism to bring novel therapies to patients with serious illnesses in a timely fashion. It is also tangible evidence of the vision and perseverance of a number of members of the Division of Cancer Treatment under the direction of Dr. Bruce Chabner, in whose honor this symposium is given.

Key Words. Paclitaxel • Taxol^® • Cytotoxicity • Tubulin • Cisplatin

This article has been cited by other articles:

				A. C. Wolff, R. C. Donehower, M. K. Carducci, M. A. Carducci, J. R. Brahmer, Y. Zabelina, M. O. Bradley, F. H. Anthony, C. S. Swindell, P. A. Witman, et al. Phase I Study of Docosahexaenoic Acid-Paclitaxel: a Taxane-Fatty Acid Conjugate with a Unique Pharmacology and Toxicity Profile Clin. Cancer Res., September 1, 2003; 9(10): 3589 - 3597. [Abstract] [Full Text] [PDF]